LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LivaNova PLC

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on LivaNova, with a price target of $85.00. Maeder covers the He...

Piper Sandler Remains a Buy on LivaNova (LIVN)

In a report released today, Matt Miksic from Barclays maintained a Hold rating on LivaNova, with a price target of $58.00. According to TipRanks, M...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LIVN	$55.29	+3.50%	392.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LIVN	$55.29	+3.5%	392.78K
3
4
5
6

LIVN

LIVN

Get LivaNova PLC Data in Excel

Get LivaNova PLC Data in Excel